REG - Scancell Hlds - Scancell to speak at World Vaccine Congress Europe

Scancell HoldingsAnnouncement

18/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231018:nRSR4407Qa&default-theme=true

RNS Number : 4407Q  Scancell Holdings Plc  18 October 2023

18 October 2023

 

Scancell Holdings plc

("Scancell" or the "Company")

 

 

Scancell to present at the 2023 World Vaccine Congress Europe

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, today announces Professor
Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of
Scancell, will be presenting at the 2023 World Vaccine Congress Europe
(https://www.terrapinn.com/conference/world-vaccine-congress-europe/index.stm)
, taking place on 17-19 October in Barcelona, Spain.

 

 

Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of
Scancell, commented: "Following the recent announcement
(https://www.scancell.co.uk/scancell-announces-positive-data-from-the-first-stage-in-its-phase-2-scope-trial-with-scib1-cancer-vaccine-delivered-by-needle-free-injection-for-advanced-melanoma)
of positive data from the first stage in our Phase 2 SCOPE trial with SCIB1
cancer vaccine for advanced melanoma, I am excited to join other leading
experts in the field to discuss the ongoing clinical progress of our two lead
cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 at this prestigious forum
within the vaccine community."

 

 

The title, timing and location of the presentation are as follows:

 

Presentation title                      Clinical update
on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting
citrullination

Speaker
Prof Lindy Durrant

Session date and time              11:00, 19 October 2023

Location
Room 2

 

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 ICR Consilium                                                                +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                   scancell@consilium-comms.com

 

 

About the SCOPE Phase 2 clinical trial

 

SCOPE is an open label, multicohort, multicentre, Phase 2 study of SCIB1 in
patients with advanced unresectable melanoma receiving either nivolumab with
ipilimumab or pembrolizumab. SCIB1 is a deoxyribonucleic acid (DNA) plasmid
vaccine encoding two CD8 epitopes from the melanoma antigens
tyrosinase-related protein-2 and glycoprotein 100 (gp100), plus two CD4
epitopes from gp100.   The purpose of the study is to determine whether the
addition of SCIB1 to standard of care checkpoint inhibitors can improve the
objective response rate (ORR) of patients with advanced melanoma relative to
the checkpoint inhibitors alone. The ORR is defined as the proportion of
patients with a complete or partial response at any time after the start of
treatment.  During the first stage of the SCOPE trial reported here, patients
received SCIB1 in combination with the best treatment currently available,
namely the CPIs nivolumab and ipilimumab. The First Stage milestone was
protocolled to demonstrate at least a 70% ORR with an 80% power ie at least
8/15 patients responding, assessed by radiological imaging. Further
information relating to the clinical trial can be found on the Company's
website at  https://www.scancell.co.uk

and at https://classic.clinicaltrials.gov/ct2/show/NCT04079166
(https://classic.clinicaltrials.gov/ct2/show/NCT04079166)

 

 

About the ModiFY Phase 1/2 clinical trial

 

ModiFY is an open-label, multicohort, multicentre, adaptive Phase 1/2 trial of
Modi-1 in patients with unresectable HGSOC, SCCHN, TNBC or RCC. The Modi-1
peptides are linked to AMPLIVANT(®), a potent adjuvant which is the subject
of a worldwide licensing and collaboration agreement with ISA Pharmaceuticals
for the manufacturing, development, and commercialisation of Modi-1. Modi-1
stimulates CD4 T cells which may directly impact tumour growth; however, in
some patients these T cells may need to be protected by CPIs if the tumour
environment is highly immunosuppressive. Patients are therefore treated with
Modi-1 alone or, if eligible for standard of care CPI, with Modi-1 plus a
CPI.

 

Cohort 1 of the study confirmed the safety profile of a low dose of two
citrullinated vimentin peptides. The objective for Cohort 2 of the trial was
to assess the safety of the two citrullinated vimentin peptides plus an
enolase peptide at a higher dose. Based on the safety data from Cohort 2, the
ModiFY trial was expanded at this recommended Phase 2 dose for Modi-1
monotherapy in all four tumour types. In parallel, Cohort 3 recruited patients
to receive low dose Modi-1 plus a CPI to assess safety of the combination
prior to testing the higher dose of Modi-1 in Cohort 4.

 

Further information relating to the clinical trial can be found on the
Company's website at https://www.scancell.co.uk (https://www.scancell.co.uk)
and at https://clinicaltrials.gov/ct2/show/NCT05329532
(https://clinicaltrials.gov/ct2/show/NCT05329532)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFMFWWEDSEFS